5395242026-07-012026-09-305395242026-09-305395242026-03-315395242026-04-012026-09-305395242026-07-012026-09-30in-capmkt:OtherExpenses1Member5395242026-07-012026-09-30in-capmkt:OtherExpenses2Member5395242026-04-012026-09-30in-capmkt:OtherExpenses1Member5395242026-04-012026-09-30in-capmkt:OtherExpenses2Member5395242026-09-30OtherNoncurrentFinancialAssetsDomain15395242026-09-30OtherNoncurrentAssetsDomain15395242026-09-30OtherNoncurrentAssetsDomain25395242026-09-30OtherCurrentFinancialAssetsDomain15395242026-09-30OtherCurrentAssetsDomain15395242026-09-30OtherNoncurrentFinancialLiabilitiesDomain15395242026-09-30OtherNoncurrentFinancialLiabilitiesDomain25395242026-09-30OtherCurrentFinancialLiabilitiesDomain15395242026-09-30OtherCurrentFinancialLiabilitiesDomain25395242026-09-30OtherCurrentLiabilitiesDomain15395242026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15395242026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares539524LALPATHLABNOTLISTEDINE600L01024Dr. Lal Path Labs Ltd.Main BoardEquity2026-04-012027-03-312026-11-042026-09-25INRMillionsQuarterlySecond quarterSingle segmentThe business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.2026-11-0411:49:002026-11-0413:20:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated8739000000343000000908200000016190000000013860000007000000046900000029320000006476000000260600000002606000000658000000800000066600000001940000000000-10000001939000000-15000000192400000019220000001700000019070000001700000016780000001011.5111.470011.5111.47i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 October, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2026 and they have expressed an unmodified conclusion on the aforesaid results. <br /> ii. As at 30 September,2026, the Parent company has the following subsidiaries: <br /> Subsidiaries <br /> Paliwal Diagnostics Private Limited <br /> Dr. Lal PathLabs Nepal Private Limited <br /> Dr. Lal PathLabs Bangladesh Private Limited <br /> Dr. Lal Ventures Private Limited <br /> PathLabs Unifiers Private Limited <br /> Dr Lal Pathlabs FZCO (w.e.f 12 June , 2026) <br /> Shahbazker Diagnostics Centre Private Limited <br /> (w.e.f 1 May, 2026) <br /> Step-down subsidiaries <br /> Centrapath Labs Private Limited <br /> APRL PathLabs Private Limited <br /> Chanre Laboratory Private Limited <br /> Sunshine Healthcare Limited <br /> (w.e.f 4 August, 2026) <br /> Dr Lal PathLabs Indomed LLC <br /> (w.e.f 19 August, 2026) <br /> Associate Company <br /> Neuome Technologies Private Limited <br /> (w.e.f 27 August, 2026) <br /> iii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). <br /> <br /> iv. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. <br /> <br /> <br /> v. During the quarter and six months ended 30 September 2026, the Parent Company has issued 211,050 and 293,800 equity shares of face value of INR 10 each respectively , to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022"). <br /> <br /> vi. The Board of Directors of the Parent Company have approved second interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 4 November, 2026 <br /> <br /> The Board of Directors of the Parent Company had approved an interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 24 July, 2026 and this was paid on 11 August, 2026 <br /> <br /> The Board of Directors of the Company had proposed final dividend of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The same was approved by the shareholders in the Annual General Meeting held on 25 July, 2026 and this was paid on 31 July, 2026 <br /> <br /> vii. Acquistions during the half year ended 30 September, 2026 <br /> a. During the six months ended 30 September, 2026, the Parent Company has acquired 100% Stake in Shahbazkers Diagnostic Centre Private Limited (“SDCPL”) on 1 May, 2026 as per the terms and conditions of the Share Purchase Agreement for a cash consideration of INR 200 million. Pursuant to completion of the aforesaid acquisition, Shahbazkers Diagnostic Centre Private Limited has now become a wholly-owned subsidiary of the Company. SDCPL is primarily engaged in providing diagnostics and healthcare services. The acquisition was accounted for as a business combination using the acquisition method of accounting, in accordance with Ind AS 103 ‘Business Combination’. The Purchase price has been allocated on a provisional basis to the net identifiable assets resulting in goodwill of INR 143 million. <br /> b. During the six months ended 30 September 2026, A wholly owned subsidiary, Dr Lal Pathlabs FZCO has been incorporated in Dubai, United Arab Emirates. The Parent Company has subscribed to 19,135 equity shares for AED 1000 each for a total consideration of AED 19 million. <br /> <br /> Dr Lal Pathlabs FZCO (wholly owned subsidiary) has incorporated a Company named Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan and has subscribed to 70% of its share capital. <br /> c. During the six months ended 30 September 2026, the Parent Company has made a further investment of INR 77.50 million in its wholly owned subsidiary, Dr. Lal Ventures Private Limited, through subscription of additional equity shares. <br /> d. The Board of Directors of Dr Lal PathLabs FZCO (a wholly owned subsidiary) in their meeting held on 24 July 2026 has approved acquisition of equity stake of 80% stake and to purchase another 20% equity stake in tranches in Sunshine Healthcare Limited located in Ghana engaged in diagnostics business for a total consideration not exceeding GHS 57 million. The acquisition was accounted for as a business combination using the acquisition method of accounting, in accordance with Ind AS 103 ‘Business Combination’. The Purchase price has been allocated on a provisional basis to the net identifiable assets resulting in goodwill of INR 239 million. <br /> e. The Board of Directors of Dr. Lal Ventures Private Limited (a wholly owned subsidiary) in their meeting held on 24 July 2026 had approved subscription of equity stake of 30% in Neuome Technologies Private Limited engaged in developing innovative solutions in sample preservation, pre-analytical technologies and bio banking business for a consideration of INR 35 million. The said subscription was completed on 27 August,2026 as per the terms and conditions of the Share subscription agreement. Pursuant to completion of the aforesaid subscription, Neuome Technologies Private Limited has now become associate of the Group and is accounted for using the equity method in accordance with IND AS 28 'Investment in Associates and Joint ventures'. <br /> viii. On 24 September 2026, the Board of Directors of the Parent Company approved the acquisition of a 70% stake in SN Genelab Private Limited ("SN Gene") for a cash consideration of up to INR 1,680 million, plus a certain performance-linked earn-out capped at INR 315 million. The transaction was concluded on 1 October 2026, and SN Gene has become a subsidiary of the Company w.e.f 1 October, 2026. SN Gene is primarily engaged in business of providing Diagnostics- Genomics Services. <br /> <br /> ix. Subsequent to 30 September 2026, the Parent Company invested an additional INR 303 million in Pathlabs Unifiers Private Limited (PUPL) through subscription to additional equity shares. The funds were utilized by PUPL to acquire the remaining 30% stake in Centrapath Labs Private Limited (CPL) for a consideration of INR 303 million, resulting in CPL becoming a wholly owned subsidiary of PUPL. <br /> x. The shareholders of the Parent Company on 07 December, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed 19 December, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on 22 December, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter and six months ended 30 September, 2025 have been restated to give effect to the allotment of the bonus shares. <br /> <br /> <br /> xi. On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by INR 301.00 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount as “Impact of Labour Codes” under “Exceptional Item” in the Consolidated Statement of Profit and Loss for the year ended 31 March, 2026. <br /> <br /> xii. During the previous year, the Group has regrouped manpower cost aggregating to INR 86 million and INR 167 million respectively for the quarter and half year ended 30 September, 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract. <br /> <br /> <br /> xiii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. <br /> <br /> xiv. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure-B for Consolidated Cash Flow Statement. <br /> <br /> 2026-04-012026-09-30UnauditedConsolidated167160000006620000001737800000031360000000027130000001330000009130000005590000000124850000004893000000048930000001255000000-7000000124800000003645000000000-10000003644000000-1000000364300000036170000002700000036160000002700000016780000001021.6521.610021.6521.61Fees to collection centers/channel partners1289000000Other expenses1643000000Fees to collection centers/channel partners2447000000Other expenses31430000005214000000490000003250000005857000000170100000080000000340000000001556000000155600000083600000016500000015745000000564000000526900000014130000003435000000736400000022000000505000000180080000002590000001883100000000345760000001678000000257670000002744500000035000000027795000000000018590000001859000000260000001900000001904000000016500000016910000001856000000146500000033210000004000000008330000003230000004877000000678100000034576000000Other financial assets1556000000Other non-current assets14000000Non-current tax assets (net)151000000Other financial assets505000000Other current assets259000000Lease liabilities1724000000Other financial liabilities135000000Lease liabilities609000000Other financial liabilities856000000Other current liabilities400000000133000000-125000000-3440000000-4600000000-190000000500000000-18000000091300000001020000000-10600000000035100000089000000000-187000000009100000049840000000009620000000402200000000023600000000004000000399000000000148000000000000000000004130000000-974000000-1340000000000000162000000000193000000151300000000-131000000-167500000010070000000100700000024280000003435000000Remeasurement of the defined benefit obligations-8000000-8000000Remeasurement of the defined benefit obligations9000000900000010000005000000Exchange differences on translation of foreign operations-6000000-6000000Exchange differences on translation of foreign operations-5000000-500000000-15000000-1000000